Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-003514

Options or other derivatives

  • CHIEF SCIENTIFIC OFFICER acquired 171,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-02-06 Grant or award : show line 1 in the form Stock Option (right to buy) +171,000 171,000 D
Loading xslF345X05/form4-02102025_100234.xml…